Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• The average recommendation for Twist Bioscience Corporation (NASDAQ:TWST) is a "Moderate Buy," with nine out of eleven analysts rating it as a buy.
• Twist Bioscience reported a quarterly revenue of $96.06 million, slightly exceeding analyst estimates, while the earnings per share (EPS) was reported at ($0.47).
• Institutional investors have recently increased their stakes in Twist Bioscience, with notable increases from ARK Investment Management and Vanguard Group.

Shares of Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $49.40.

TWST has been the topic of several analyst reports. Evercore ISI set a $46.00 target price on shares of Twist Bioscience in a research note on Monday, August 4th. Cowen restated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th.

Twist Bioscience Price Performance

TWST stock opened at $25.31 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience has a 52 week low of $24.07 and a 52 week high of $55.33. The firm's fifty day moving average is $30.52 and its 200 day moving average is $34.18. The firm has a market cap of $1.53 billion, a P/E ratio of -17.46 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares in the company, valued at $3,951,157.35. The trade was a 2.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 2,265 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the transaction, the chief executive officer owned 634,740 shares in the company, valued at $16,350,902.40. This represents a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,911 shares of company stock worth $288,159. 3.01% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its stake in Twist Bioscience by 2.5% during the second quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company's stock valued at $235,472,000 after acquiring an additional 158,846 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Twist Bioscience by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after acquiring an additional 60,276 shares during the last quarter. William Blair Investment Management LLC boosted its position in shares of Twist Bioscience by 2.6% during the 2nd quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company's stock valued at $143,724,000 after acquiring an additional 99,737 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Twist Bioscience by 186.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after acquiring an additional 1,588,587 shares during the last quarter. Finally, EdgePoint Investment Group Inc. boosted its position in shares of Twist Bioscience by 114.3% during the 2nd quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company's stock valued at $87,779,000 after acquiring an additional 1,272,732 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.